Prognostic Role of Early and End-of-Neoadjuvant Treatment 18F-FDG PET/CT in Patients With Breast Cancer

被引:17
作者
Garcia Vicente, Ana Maria [1 ]
Amo-Salas, Mariano [2 ]
Relea Calatayud, Fernanda [3 ]
Munoz Sanchez, Maria del Mar [4 ]
Pena Pardo, Francisco Jose [1 ]
Jimenez Londono, German Andres [1 ]
Alvarez Cabellos, Ruth [5 ]
Espinosa Aunion, Ruth [6 ]
Soriano Castrejon, Angel [1 ]
机构
[1] Univ Gen Hosp, Dept Nucl Med, C Obispo Rafael Torija S-N, Ciudad Real 13005, Spain
[2] Univ Castilla La Mancha, Dept Math, E-13071 Ciudad Real, Spain
[3] Univ Gen Hosp, Dept Pathol, Ciudad Real, Spain
[4] Virgen de la Luz Hosp, Dept Oncol, Cuenca, Spain
[5] Virgen de la Salud Hosp, Dept Oncol, Toledo, Spain
[6] La Mancha Ctr Hosp, Dept Oncol, Ciudad Real, Spain
关键词
FDG PET/CT; neoadjuvant chemotherapy; response; prognosis; breast cancer; PATHOLOGICAL COMPLETE RESPONSE; POSITRON-EMISSION-TOMOGRAPHY; EARLY PREDICTION; CHEMOTHERAPY PREDICTS; TUMOR METABOLISM; SYSTEMIC THERAPY; BLOOD-FLOW; TRASTUZUMAB; HIGHLIGHTS; CONSENSUS;
D O I
10.1097/RLU.0000000000001191
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim: To determine the use of early and final treatment F-18-FDG PET/CT in the prediction of response to neoadjuvant chemotherapy (NAC) and its role in the prognosis of patients with locally advanced breast cancer (LABC). Methods: One hundred thirty-two patients underwent a baseline FDG PET/CT (PET-1) after the second course of chemotherapy (PET-2) and after the last course (PET-3). Breast tumors were categorized into molecular phenotypes and risk categories according to the biological prognostic factors obtained by immunohistochemistry. PET/CT scans were semiquantitatively evaluated, obtaining the Delta% SUV1-2 and SUV1-3 in primary tumor and axillary lymph nodes to establish response groups attending to EORTC criteria. Moreover, a binary assessment was obtained classifying the studies as positive or negative. Histopathological response was obtained in breast and lymph node specimens. Overall survival (OS) and disease-free survival (DFS) were obtained after the follow-up. ROC analysis was performed to determine a cutoff value of Delta% SUV1-2 and SUV1-3 for the prediction of response and prognosis. Relations between phenotypes, metabolic behavior, final histopathological response, OS, and DFS were evaluated. Results: In binary analysis, only PET-3 was able to predict histopathological response in lymph nodes. The cutoff values of %Delta SUV1-2 and %. SUV1-3 with the best sensitivity and specificity in the prediction of response in breast tumor were 62% (Se: 70% and Sp: 69%) and 84% (Se: 70% and Sp: 88%). A%Delta SUV1-3 of 74% in breast tumor was a predictor of DFS (AUC = 0.647; P = 0.037, Se: 52% and Sp: 66%). Kaplan-Meier analysis revealed significant relations between the binary lymph node assessment of PET-3 with OS (P = 0.016, chi(2) = 5.78) and DFS (P = 0.003, chi(2) = 9.10). Conclusions: End-of-treatment F-18-FDG PET/CT was a predictor of lymph node response and prognosis. Most of metabolic response variables related to histopathological response showed association with the prognosis.
引用
收藏
页码:E313 / E322
页数:10
相关论文
共 55 条
[1]  
Bassa P, 1996, J NUCL MED, V37, P931
[2]   Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J].
Bear, HD ;
Anderson, S ;
Smith, RE ;
Geyer, CE ;
Mamounas, EP ;
Fisher, B ;
Brown, AM ;
Robidoux, A ;
Margolese, R ;
Kahlenberg, MS ;
Paik, S ;
Soran, A ;
Wickerham, DL ;
Wolmark, N .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2019-2027
[3]   [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy [J].
Berriolo-Riedinger, Alina ;
Touzery, Claude ;
Riedinger, Jean-Marc ;
Toubeau, Michel ;
Coudert, Bruno ;
Arnould, Laurent ;
Boichot, Christophe ;
Cochet, Alexandre ;
Fumoleau, Pierre ;
Brunotte, Francois .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (12) :1915-1924
[4]   Immunohistochemical Surrogate Markers of Breast Cancer Molecular Classes Predicts Response to Neoadjuvant Chemotherapy A Single Institutional Experience With 359 Cases [J].
Bhargava, Rohit ;
Beriwal, Sushil ;
Dabbs, David J. ;
Ozbek, Umut ;
Soran, Atilla ;
Johnson, Ronald R. ;
Brufsky, Adam M. ;
Lembersky, Barry C. ;
Ahrendt, Gretchen M. .
CANCER, 2010, 116 (06) :1431-1439
[5]   Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].
Buzdar, AU ;
Ibrahim, NK ;
Francis, D ;
Booser, DJ ;
Thomas, ES ;
Theriault, RL ;
Pusztai, L ;
Green, MC ;
Arun, BK ;
Giordano, SH ;
Cristofanilli, M ;
Frye, DK ;
Smith, TL ;
Hunt, KK ;
Singletary, SE ;
Sahin, AA ;
Ewer, MS ;
Buchholz, TA ;
Berry, D ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685
[6]   American joint committee on cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome [J].
Carey, LA ;
Metzger, R ;
Dees, EC ;
Collichio, F ;
Sartor, CI ;
Ollila, DW ;
Klauber-DeMore, N ;
Halle, J ;
Sawyer, L ;
Moore, DT ;
Graham, ML .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (15) :1137-1142
[7]   18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis [J].
Cheng, Xu ;
Li, Yongjun ;
Liu, Biao ;
Xu, Zhaoqiang ;
Bao, Lihua ;
Wang, Jie .
ACTA RADIOLOGICA, 2012, 53 (06) :615-627
[8]   Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].
Cortazar, Patricia ;
Zhang, Lijun ;
Untch, Michael ;
Mehta, Keyur ;
Costantino, Joseph P. ;
Wolmark, Norman ;
Bonnefoi, Herve ;
Cameron, David ;
Gianni, Luca ;
Valagussa, Pinuccia ;
Swain, Sandra M. ;
Prowell, Tatiana ;
Loibl, Sibylle ;
Wickerham, D. Lawrence ;
Bogaerts, Jan ;
Baselga, Jose ;
Perou, Charles ;
Blumenthal, Gideon ;
Blohmer, Jens ;
Mamounas, Eleftherios P. ;
Bergh, Jonas ;
Semiglazov, Vladimir ;
Justice, Robert ;
Eidtmann, Holger ;
Paik, Soonmyung ;
Piccart, Martine ;
Sridhara, Rajeshwari ;
Fasching, Peter A. ;
Slaets, Leen ;
Tang, Shenghui ;
Gerber, Bernd ;
Geyer, Charles E., Jr. ;
Pazdur, Richard ;
Ditsch, Nina ;
Rastogi, Priya ;
Eiermann, Wolfgang ;
von Minckwitz, Gunter .
LANCET, 2014, 384 (9938) :164-172
[9]   FDG PET/CT for monitoring response to neoadjuvant chemotherapy in breast cancer patients [J].
Dalus, Katharina ;
Rendl, Gundula ;
Rettenbacher, Lukas ;
Pirich, Christian .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (10) :1992-1993
[10]   Tumor metabolism and blood flow changes by positron emission tomography: Relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer [J].
Dunnwald, Lisa K. ;
Gralow, Julie R. ;
Ellis, Georgiana K. ;
Livingston, Robert B. ;
Linden, Hannah M. ;
Specht, Jennifer M. ;
Doot, Robert K. ;
Lawton, Thomas J. ;
Barlow, William E. ;
Kurland, Brenda F. ;
Schubert, Erin K. ;
Mankoff, David A. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) :4449-4457